Search

Your search keyword '"Machala, L"' showing total 287 results

Search Constraints

Start Over You searched for: Author "Machala, L" Remove constraint Author: "Machala, L"
287 results on '"Machala, L"'

Search Results

2. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

4. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

5. CuFeO2 prepared by electron cyclotron wave resonance-assisted reactive HiPIMS with two magnetrons and radio frequency magnetron sputtering.

8. Swift heavy ion irradiation-induced amorphous iron and Fe–Si oxide phases in metallic 57Fe layer vacuum deposited on surface of SiO2/Si

9. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

10. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

11. The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people†

12. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

13. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

16. Change in Magnetic Anisotropy at the Surface and in the Bulk of FINEMET Induced by Swift Heavy Ion Irradiation

17. Observational cohort study of rilpivirine (RPV) utilization in Europe

18. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

20. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

21. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

22. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

24. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

26. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

28. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

32. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

33. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

35. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

36. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

37. Liver-related death among HIV/hepatitis C virus-co-infected individuals

38. HIV resistance testing and detected drug resistance in Europe

39. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

40. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

42. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression : A prospective cohort study

43. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe

44. Infection-related and -unrelated malignancies, HIV and the aging population

45. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

46. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

47. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors

48. Assessment, diagnosisand treatment of Human Immunodeficiency Virus (HIV)-associated neurocognitive disorders (HAND): A consensus report of the mind exchange program

50. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

Catalog

Books, media, physical & digital resources